TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(U.S. dollars in millions)
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating activities: | ||||
| Net income (loss) | $(390) | 77 | $(1,684) | (1,082) |
| Adjustments to reconcile net income (loss) to net cash provided by operations: | ||||
| Depreciation and amortization | 259 | 283 | 790 | 887 |
| Impairment of goodwill | 600 | — | 1,000 | 700 |
| Impairment of long-lived assets and assets held for sale | (51) | 48 | 758 | 310 |
| Net change in operating assets and liabilities | 317 | (227) | (190) | (364) |
| Deferred income taxes – net and uncertain tax positions | (53) | (199) | (666) | (349) |
| Stock-based compensation | 29 | 31 | 89 | 93 |
| Other items * | 2 | (5) | 597 | 18 |
| Net loss (gain) from sale of business and long-lived assets | (21) | (3) | (22) | (29) |
| Net cash provided by (used in) operating activities | 693 | 5 | 672 | 184 |
| Investing activities: | ||||
| Beneficial interest collected in exchange for securitized accounts receivables | 339 | 362 | 951 | 1,056 |
| Purchases of property, plant and equipment and intangible assets | (148) | (149) | (369) | (407) |
| Proceeds from sale of business and long-lived assets | 38 | 10 | 39 | 68 |
| Acquisition of businesses, net of cash acquired | — | — | (15) | — |
| Purchases of investments and other assets | (1) | (38) | (56) | (44) |
| Proceeds from sale of investments | 40 | — | 40 | |
| Other investing activities | — | (1) | — | (6) |
| Net cash provided by (used in) investing activities | 268 | 184 | 590 | 667 |
| Financing activities: | ||||
| Repayment of senior notes and loans and other long term liabilities | — | (1,000) | (956) | (4,152) |
| Purchase of shares from non-controlling interests | — | — | (64) | — |
| Dividends paid to non-controlling interests | — | — | (78) | — |
| Proceeds from senior notes, net of issuance costs | — | — | — | 2,451 |
| Proceeds from short term debt | — | 700 | — | 700 |
| Repayment of short term debt | — | (200) | — | (200) |
| Other financing activities | — | (76) | (19) | (136) |
| Net cash provided by (used in) financing activities | — | (576) | (1,117) | (1,337) |
| Translation adjustment on cash and cash equivalents | 100 | (33) | (53) | (98) |
| Net change in cash, cash equivalents and restricted cash | 1,061 | (420) | — 92 | (584) |
| Balance of cash, cash equivalents and restricted cash at beginning of period | 2,258 | 2,670 | 3,227 | 2,834 |
| Balance of cash, cash equivalents and restricted cash at end of period | $3,319 | 2,250 | 3,319 | 2,250 |
| Cash and cash equivalents | 3,319 | 2,249 | 3,319 | 2,249 |
| Restricted cash included in other current assets | — | 1 | — | 1 |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | 3,319 | 2,250 | 3,319 | 2,250 |
| Non-cash financing and investing activities: | ||||
| Beneficial interest obtained in exchange for securitized accounts receivables | $332 | 376 | $964 | 1,090 |
| Dividend declared to non-controlling interests | $— | 67 | $— | 67 |
| * | Adjustment in the nine-months period ended September 30, 2024 mainly relates to an agreement with the Israeli Tax Authorities to settle certain litigation in an amount of $495 million relating to taxes payable for the years 2008 through 2020. |
|---|
Amounts may not add up due to rounding
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.